Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female, aged \>=18 years.~* Subject must have histologic diagnosis of breast carcinoma.~* Subject must have documented measurable metastatic breast cancer by appropriate radiologic imaging.~* Subject must have previous anthracyclin-based adjuvant regimen and disease-free status for at least one year following the completion of adjuvant therapy.~* Subject must have ECOG performance status 0, 1, or 2.~* Subject must have life expectancy \> 6 months~* Subject must have left ventricular ejection fraction \>=55% as determined by MUGA scan.~* Subject must have normal organ function, except if abnormal due to tumor involvement:~  * Adequate bone marrow function (platelets \>=100 X 10\^9/L, hemoglobin \>=90 g/L, Neutrophils \>=1.5 X 10\^9/L)~ * Adequate renal function (serum creatinine \< 2 X the upper limit of normal (ULN)~ * Adequate liver function (bilirubin \< 2 times ULN, AST or ALT \< 2 times ULN in the absence of liver metastasis, AST or ALT \< 5 times ULN in the presence of liver metastasis.~* Women of childbearing potential must be using adequate contraception and have a negative pregnancy test at the time of enrollment.~* Subject must be able to understand and give informed consent.~Exclusion Criteria:~* Age \> 75 years old.~* Subject who is pregnant or breastfeeding or is unwilling to use adequate contraception.~* Subject who has had a previous chemotherapy for metastatic disease.~* Subject who has history of cardiac disease, with New York Heart Association Class II or greater with congestive heart failure.~* Subject who has clinically significant hepatic disease in regard to Hepatitis B, Hepatitis C, cirrhosis, or other liver diseases unrelated to the underlying metastatic breast cancer.~* Subject who has uncontrolled bacterial, viral, or fungal infection.~* Subject who exhibits confusion or disorientation.~* Subject with any condition which would prevent adequate follow-up.~* Subject who has received radiotherapy in the last 4 weeks.~* Subject with any other active primary tumor under treatment, except basal cell carcinoma of the skin, or carcinoma in situ of the cervix.~* Subject who has brain metastasis.~* Subject who is not able to give informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Caelyx 35 mg/m2 and Cyclophosphamide 600 mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).